United States - English - NLM (National Library of Medicine)

exelan pharmaceuticals inc. - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 20 mg - trospium chloride tablet is a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride tablets are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma. - known hypersensitivity to the drug or its ingredients. angioedema, rash and anaphylactic reaction have been reported. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of trospium chloride tablets in pregnant women. trospium chloride tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride tablets treatment are encouraged to contact their physician. risk summary based on animal data, trospium chloride is predicted to have a low probability of increased risk of adverse developmental outcomes, above background risk. adverse d

United States - English - NLM (National Library of Medicine)

avkare - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 20 mg - trospium chloride tablets, usp are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride tablets are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma. - known hypersensitivity to the drug or its ingredients. angioedema, rash and anaphylactic reaction have been reported. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of trospium chloride tablets in pregnant women. trospium chloride tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride treatment are encouraged to contact their physician.   risk summary based on animal data, trospium chloride tablets are predicted to have a low probability of increased risk of adverse developmental outcomes, above b

United States - English - NLM (National Library of Medicine)

apotex corp. - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 20 mg - trospium chloride tablets, usp are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride tablets are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma. - known hypersensitivity to the drug or its ingredients. angioedema, rash and anaphylactic reaction have been reported. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of trospium chloride tablets in pregnant women. trospium chloride tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride treatment are encouraged to contact their physician.  risk summary based on animal data, trospium chloride tablets are predicted to have a low probability of increased risk of adverse developmental outcomes, above background risk.

United States - English - NLM (National Library of Medicine)

cipla usa inc., - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 20 mg - trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride tablets are contraindicated in patients with: teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of trospium chloride tablets in pregnant women. trospium chloride tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride tablets treatment are encouraged to contact their physician. risk summary based on animal data, trospium chloride is predicted to have a low probability of increased risk of adverse developmental outcomes, above background risk. adverse developmental findings were not observed to correlate with dose in rats or in rabbits. no increased risk above background was observed in rats and rabbits treated at an exposure

United States - English - NLM (National Library of Medicine)

golden state medical supply, inc. - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 60 mg - trospium chloride extended-release capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride extended-release capsules are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma - known hypersensitivity to the drug or its ingredients. angioedema, rash and anaphylactic reaction have been reported. teratogenic effects pregnancy category c : there are no adequate and well-controlled studies of trospium chloride extended-release capsules in pregnant women.  trospium chloride extended-release capsules should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride extended-release capsules treatment are encouraged to contact their physician. trospium chloride was not teratogenic at statistically significant levels in rats

United States - English - NLM (National Library of Medicine)

actavis pharma, inc. - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 60 mg - trospium chloride extended-release capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride extended-release capsules are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma - known hypersensitivity to the drug or its ingredients. angioedema, rash and anaphylactic reaction have been reported. teratogenic effects pregnancy category c : there are no adequate and well-controlled studies of trospium chloride extended-release capsules in pregnant women.  trospium chloride extended-release capsules should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride extended-release capsules treatment are encouraged to contact their physician. trospium chloride was not teratogenic at statistically significant levels in rats

United States - English - NLM (National Library of Medicine)

bluepoint laboratories - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 60 mg - trospium chloride extended-release capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride extended-release capsules are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma - known hypersensitivity to the drug or its ingredients. angioedema, rash and anaphylactic reaction have been reported. teratogenic effects pregnancy category c : there are no adequate and well-controlled studies of trospium chloride extended-release capsules in pregnant women.  trospium chloride extended-release capsules should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride extended-release capsules treatment are encouraged to contact their physician. trospium chloride was not teratogenic at statistically significant levels in rats

United States - English - NLM (National Library of Medicine)

padagis us llc - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 20 mg - trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride tablets are contraindicated in patients with: teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of trospium chloride tablets in pregnant women. trospium chloride tablets should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride tablets treatment are encouraged to contact their physician. risk summary based on animal data, trospium chloride is predicted to have a low probability of increased risk of adverse developmental outcomes, above background risk. adverse developmental findings were not observed to correlate with dose in rats or in rabbits. no increased risk above background was observed in rats and rabbits treated at an exposure approximately equiv

United States - English - NLM (National Library of Medicine)

heritage pharmaceuticals inc. d/b/a avet pharmaceuticals inc. - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 20 mg - trospium chloride tablets are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride tablets are contraindicated in patients with: - urinary retention - gastric retention - uncontrolled narrow-angle glaucoma. - known hypersensitivity to the drug or its ingredients. angioedema, rash and anaphylactic reaction have been reported. teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of trospium chloride in pregnant women. trospium chloride should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride treatment are encouraged to contact their physician. risk summary based on animal data, trospium chloride is predicted to have a low probability of increased risk of adverse developmental outcomes, above background risk. adverse developmental find

United States - English - NLM (National Library of Medicine)

padagis us llc - trospium chloride (unii: 1e6682427e) (trospium - unii:t4y8ork057) - trospium chloride 60 mg - trospium chloride extended-release capsules are a muscarinic antagonist indicated for the treatment of overactive bladder (oab) with symptoms of urge urinary incontinence, urgency, and urinary frequency. trospium chloride extended-release capsules are contraindicated in patients with: teratogenic effects pregnancy category c: there are no adequate and well-controlled studies of trospium chloride extended-release capsules in pregnant women. trospium chloride extended-release capsules should be used during pregnancy only if the potential benefit to the patient outweighs the risk to the patient and fetus. women who become pregnant during trospium chloride extended-release capsules treatment are encouraged to contact their physician. trospium chloride was not teratogenic at statistically significant levels in rats or rabbits administered doses up to 200 mg/kg/day. this corresponds to systemic exposures up to approximately 16 and 32 times, respectively (based on auc), the clinical exposure at the maximum recommen